CENTESSA-Icon-Logo

Arjun Goyal MD MPHIL MBA

Co-Founder and Managing Director

Vida Ventures

Dr. Arjun Goyal, MD, MPhil, MBA, is a Co-Founder and Managing Director of Vida Ventures. Arjun focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Arjun serves as a Director on the boards of Scorpion Therapeutics, Quanta Therapeutics, Pionyr Immunotherapeutics and has been involved in Vida Venture’s investments in Homology Medicines (NASDAQ: FIXX), Peloton Therapeutics (acquired by Merck & Co.), and Asklepios Bio (acquired by Bayer). Before co-founding Vida Ventures, Arjun was a life sciences investor at 5AM Ventures.

Arjun received his BS in Medical Science, Diploma in French, and his MD degree from the Universities of Melbourne and Oxford. He completed his postgraduate clinical training in Internal Medicine in Sydney. He received his MPhil in Bioscience Enterprise from the University of Cambridge and his MBA from Harvard Business School. Arjun has received multiple awards for his work, including the American Australian Association Education Fellowship, Robert Kaplan HBS Life Science Fellowship, Oxford Clarendon Scholarship, Commonwealth Scholarship, and Gates Cambridge Scholarship.

He is a co-inventor on one patent and had served on the editorial board of an international scientific journal. He serves on the Committee for the American Australian Association Education Fellowship.

Back to Board of Directors
Scroll to Top
pipeline chart header registrational white
SerpinPC

Overview
SerpinPC is a subcutaneously administered novel inhibitor of APC being developed as a potential treatment for hemophilia, regardless of severity or inhibitor status, and may also prevent bleeding associated with other bleeding disorders. Centessa is advancing the registrational program for SerpinPC in hemophilia B, which includes a set of clinical studies with multiple components. PRESent-5, initiated in late 2022, is an observational feeder study to collect prospective observational data for minimum defined periods before switching to dosing subjects in the interventional studies. The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors). Additional information on the trials can be accessed at www.clinicaltrials.gov  (NCT05605678, NCT05789524, NCT05789537). SerpinPC is an investigational agent that has not been approved by the FDA or any other regulatory authority.

Reason to Believe in Target
Human Genetics Support

Epidemiology
~20,000 persons with hemophilia in the United States
450,000 estimated global prevalence
Disease

Hemophilia B